Who are GLYCOPYRRONIUM's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SCOPOLAMINE, Enlon-Plus, Diclofenac oral + scopolamina oral, Neostigmine + Glycopyrrolate, oxybutynin immediate release, Placebo Tablet and Nicotine Patch.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/glycopyrronium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

GLYCOPYRRONIUM — Competitive Intelligence Brief

GLYCOPYRRONIUM (GLYCOPYRRONIUM) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

marketed acetylcholine receptors Small molecule Live · refreshed every 30 min

Target snapshot

GLYCOPYRRONIUM (GLYCOPYRRONIUM). Glycopyrronium blocks acetylcholine receptors on sweat glands, reducing sweating.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
GLYCOPYRRONIUM TARGET	GLYCOPYRRONIUM		marketed		acetylcholine receptors	1961-01-01
SCOPOLAMINE	SCOPOLAMINE		marketed	Anticholinergic [EPC]	Muscarinic acetylcholine receptors	1979-01-01
Enlon-Plus	Atropine Sulfate	Alcon Labs Inc	marketed	Antimuscarinic agent	Muscarinic acetylcholine receptors	1960-01-01
Diclofenac oral + scopolamina oral	Diclofenac oral + scopolamina oral	Hospital de Clinicas de Porto Alegre	marketed	NSAID + anticholinergic combination	COX-1/COX-2 (diclofenac); muscarinic acetylcholine receptors (scopolamine)
Neostigmine + Glycopyrrolate	Neostigmine + Glycopyrrolate	Merck Sharp & Dohme LLC	marketed	Acetylcholinesterase inhibitor with anticholinergic agent	Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (glycopyrrolate)
oxybutynin immediate release	oxybutynin immediate release	Astellas Pharma Inc	marketed	Anticholinergic	Muscarinic acetylcholine receptors (M2 and M3)
Placebo Tablet and Nicotine Patch	Placebo Tablet and Nicotine Patch	The Scripps Research Institute	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GLYCOPYRRONIUM — Competitive Intelligence Brief. https://druglandscape.com/ci/glycopyrronium. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab